

FoCUS Toolkit general education: Overview of the cell and gene therapy pipeline

July 2023



NEW DIGS



The FoCUS Project has developed these slides as a resource for understanding the financial challenges of delivering and financing an advanced durable therapy.

You may review, download, copy, distribute and use the available content solely for the purpose of general education, information gathering, and/or research purposes provided you properly attribute such content to NEWDIGS, Tufts Medical Center. By using these slides, you hereby accept the [Terms of Use](#).



Disruption of Biopharma Payment System

The market of cell and gene therapies is poised to disrupt how we pay for biopharmaceutical care based on:

- Potential 'cures' for conditions with small numbers of patients
- High prices with payment 'up front'
- Performance uncertainty



Disruption Challenges

Potential 'cures' for conditions with small numbers of patients.

- Developers need to recover development costs and profits from limited numbers of patients.

High prices with payment 'up front'.


- Payers are faced with high, one-time payments when curative treatments replace chronic treatments.

Performance uncertainty

- Product approvals with limited trial size, long term clinical outcomes still being evaluated, changes in FDA label.



Expectation: 60+ product indications by 2032




Pipeline product indications:

- ❖ 72% for oncology patients
- ❖ 22% for orphan, non-oncology indications
- ❖ 6% for larger therapeutic areas such as cardiovascular conditions



Growth in spend for CGT




- ❖ Large oncology pipeline has its greatest impact on Medicare payers.
- ❖ Treatment for prevalent diseases peaks from 2025-2027 for Medicaid and Not-Medicaid or Medicare payers.



Pipeline Production

Already approved



Anticipated approvals

Rare diseases

- Sickle Cell Anemia

Oncology

- B-Cell leukemia
- Lymphoma

Ophthalmological conditions

Neurological conditions

TuftsMedicine
Tufts Medical Center



tuftsmedicine.org